Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: Comparison of different vaccine formulations

Blood

Volumn 90, Issue 9, 1997, Pages 3699-3706

  Caspar, Clemens B ^a   Levy, Shoshana ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN IDIOTYPE; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; KEYHOLE LIMPET HEMOCYANIN; PLASMID DNA; TUMOR VACCINE;

ACTIVE IMMUNIZATION; ADENOVIRUS; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR RECURRENCE;

EID: 0030735798     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.9.3699     Document Type: Article

References (33)

1. Grossbard M, Press O, Appelbaum F, Bernstein I, Nadler L: Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863, 1992
2. Levy R, Hatzubai A, Brown S, Maloney D, Dilley J: Immunoglobulin idiotype: A tumor-specific antigen for human B-cell lymphomas. in Rosenberg SA, Kaplan HS (eds): Malignant Lymphomas: Etiology, Immunology, Pathology, Treatment. New York, NY, Academic, 1982, p 95
3. Stevenson G, Elliot E, Stevenson F: Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: A therapeutic target. Fed Proc 36:2268, 1977
4. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-tdiotype antibody. N EngI J Med 306:517, 1982
5. Maloney D, Brown S, Czerwinski D, Liles T, Hart S, Miller R, Levy R: Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 80:1502, 1992
6. Brown S, Miller R, Horning S, Czerwinski D, Hart S, McElderry R, Basham T, Warnke R, Merigan T, Levy R: Treatment of B- cell lymphomas with anti-idiotype antibodies alone and in combination with alpha Interferon. Blood 73:651, 1989
7. Meeker TC, Lowder J, Maloney DC, Miller RA, Thielemans K, Warnke R, Levy R: A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65:1349, 1985
8. Meeker T, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J, Levy R: Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med 312:1658, 1985
9. Levy S, Mendel E, Kon S, Avnur Z, Levy R: Mutational hot spots in Ig V region genes of human follicular lymphomas. J Exp Med 168:475, 1988
10. Cleary M, Meeker T, Levy S, Lee E, Trela M, Sklar J, Levy R: Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell 44:97, 1986
11. Sirisinha S, Eisen H: Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci USA 68:3130, 1971
12. Lynch G, Graff R, Sirisinha S, Simms E, Eisen H: Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 69:1540, 1972
13. Hsu F, Caspar C, Czerwinski D, Kwak L, Liles T, Syrengelas A, Taidi-Laskowski B, Levy R: Tumor-specific idiotype vaccines in the treatment of patients with B cell lymphoma - Long-term results of a clinical trial. Blood 89:3129, 1997
14. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
15. Stevenson FK, Gordon J: Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. J Immunol 130:970, 1983
16. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R: Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 145:1029, 1990
17. Campbell MJ, Esserman L, Levy R: Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J Immunol 141:3227, 1988
18. Chen TT, Tao MH, Levy R: Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocytemacrophage colony-stimulating factor. J Immunol 153:4775, 1994
19. Tao MH, Levy R: Idiotype/granulocyte-macrophage colony- stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755, 1993
20. Watanabe A, Raz E, Kohsaka H, Tighe H, Baird SM, Kipps TJ, Carson DA: Induction of antibodies to a kappa V region by gene immunization. J Immunol 151:287, 1993
21. Syrengelas A, Chen TT, Levy R: DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 2:1038, 1996
22. Feigner P, Tsai Y, Sukhu L, Wheeler C, Manthorpe M, Marashall J, Cheng S: Improved cationic lipid formulations for in vivo gene therapy. Ann NY Acad Sci 772:126, 1995
23. Carrol W, Thielemans K, Dilley J, Levy R: Mouse × human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods 89:61, 1986
24. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435, 1994
25. Xu X, Dai Y, Heidenreich O, Nerenberg M: Adenovirusmediated interferon-gamma transfer inhibits growth of transplanted HTLV-1 tax tumors in mice. Hum Gene Ther 7:471, 1996
26. McGrory W, Bautista D, Graham F: A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology 163:614, 1988
27. Graham F, Smiley J: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59, 1977
28. Bett A, Prevec L, Graham F: Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 67:5911, 1993
29. Stevens T, Bossie A, Sanders V, Fernandez-Botran R, Coffman R, Mosmann T, Vitetta E: Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334:255, 1988
30. Irvine KR, Rao JB, Rosenberg SA, Restifo NP: Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156:238, 1996
31. Chen P, Wang M, Bronte V, Zhai Y, Rosenberg S, Restifo N: Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 156:224, 1996
32. Potter K, Li Y, Capra J: Antibody production in the baculovirus expression system. Int Rev Immunol 10:103, 1993
33. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996